Helix BioPharma Corp says 2021 a productive year as it anticipates results of its Phase I and II studies in lung cancer in 2022

During the second half of 2021, the company initiated efforts to validate Helix and its lead clinical program with external stakeholders to...

Related Keywords

,Slawomir Majewski ,Christof Boehler ,Richmond Hill ,Helix Biopharma Corp ,Lind Global Macro Fund ,Cello Healthcare ,Atul Deshpande ,